These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 33276565)
1. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Markovic M; Zur M; Ragatsky I; Cvijić S; Dahan A Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276565 [TBL] [Abstract][Full Text] [Related]
2. The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract. Zur M; Cohen N; Agbaria R; Dahan A Int J Pharm; 2015 Jul; 489(1-2):304-10. PubMed ID: 25957705 [TBL] [Abstract][Full Text] [Related]
3. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Zur M; Gasparini M; Wolk O; Amidon GL; Dahan A Mol Pharm; 2014 May; 11(5):1707-14. PubMed ID: 24735251 [TBL] [Abstract][Full Text] [Related]
4. Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine. Fairstein M; Swissa R; Dahan A AAPS J; 2013 Apr; 15(2):589-97. PubMed ID: 23440549 [TBL] [Abstract][Full Text] [Related]
5. Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses. Chow EC; Talattof A; Tsakalozou E; Fan J; Zhao L; Zhang X AAPS J; 2016 Nov; 18(6):1500-1511. PubMed ID: 27520379 [TBL] [Abstract][Full Text] [Related]
6. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. Zur M; Hanson AS; Dahan A Eur J Pharm Sci; 2014 Sep; 61():11-7. PubMed ID: 24262076 [TBL] [Abstract][Full Text] [Related]
7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
8. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273 [TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability. Markovic M; Zur M; Dahan A; Cvijić S Eur J Pharm Sci; 2020 Sep; 152():105440. PubMed ID: 32615260 [TBL] [Abstract][Full Text] [Related]
11. Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. Markovic M; Zur M; Fine-Shamir N; Haimov E; González-Álvarez I; Dahan A Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32214015 [TBL] [Abstract][Full Text] [Related]
12. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Tsume Y; Amidon GL Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130 [TBL] [Abstract][Full Text] [Related]
14. Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet). Li H; Cao X; Liu Y; Liu T; Wang M; Ren X; Dou Z J Ethnopharmacol; 2019 Nov; 244():112148. PubMed ID: 31400507 [TBL] [Abstract][Full Text] [Related]
15. BCS class IV drugs: Highly notorious candidates for formulation development. Ghadi R; Dand N J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572 [TBL] [Abstract][Full Text] [Related]
16. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
17. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Dahan A; Amidon GL Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230 [TBL] [Abstract][Full Text] [Related]
18. A modified physiological BCS for prediction of intestinal absorption in drug discovery. Zaki NM; Artursson P; Bergström CA Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997 [TBL] [Abstract][Full Text] [Related]
19. Purely in silico BCS classification: science based quality standards for the world's drugs. Dahan A; Wolk O; Kim YH; Ramachandran C; Crippen GM; Takagi T; Bermejo M; Amidon GL Mol Pharm; 2013 Nov; 10(11):4378-90. PubMed ID: 24094040 [TBL] [Abstract][Full Text] [Related]
20. Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by In Vivo Permeability Values. Wolk O; Markovic M; Porat D; Fine-Shamir N; Zur M; Beig A; Dahan A J Pharm Sci; 2019 Jan; 108(1):316-325. PubMed ID: 30055228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]